Abiopharma

🔍 Feeley Kevin (Executive)

Company: GeneDx Holdings Corp. (WGS)

Report Date: 2025-09-01

Detailed Transactions and Holdings:

• Acquired 717 shares of Class A Common Stock (Direct)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,474.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 378 shares of Class A Common Stock at $125.8096 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,096.00 | transaction_form_type: 4 | Footnotes: F2, F3, F4
• Sold 717 shares of Restricted Stock Unit (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,869.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
• F2: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.2050 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: Following the reported sales, in addition to the 4,096 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 134,292 shares of Class A common stock and options to purchase up to an aggregate of 27,152 shares of Class A common stock, which RSUs and options vest according to their respective terms.
• F5: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.